Form 4: AnaptysBio CFO Receives Restricted Stock Unit Grant

AnaptysBio CFO Christopher M. Murphy was granted 25,765 restricted stock units as part of an equity compensation plan.

Summary

• Christopher M. Murphy, Chief Financial Officer of AnaptysBio, Inc., was granted 25,765 restricted stock units (RSUs).
• The grant occurred on May 11, 2026.
• Each RSU represents a contingent right to receive one share of common stock upon settlement for no consideration.
• The RSUs are subject to a four-year vesting schedule, with 25% vesting annually starting May 11, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which carries a neutral sentiment.

Positives

• Equity-based compensation aligns the interests of the CFO with long-term shareholder value creation.

Negatives

• The grant results in potential future dilution for existing shareholders upon the eventual settlement and issuance of common stock.

Risks

• Vesting is contingent upon the continued service of the reporting person to the issuer.

Future Outlook

The RSUs will vest in 25% annual increments over four years, provided the reporting person remains in service to the company.

Industry Context

StockSavvy.ai notes that equity grants to executive officers are standard practice in the biotechnology sector to incentivize long-term retention and performance alignment.

Comparison to Industry Standards

• The four-year annual vesting schedule is consistent with standard corporate governance practices for executive equity compensation in the U.S. biotech industry.

Stakeholder Impact

• Shareholders may experience minor dilution upon the future settlement of these RSUs.

Next Steps

• Vesting of the first 25% of the RSU grant on May 11, 2027.

Key Dates

Keywords

AnaptysBio, ANAB, Form 4, Insider Transaction, Restricted Stock Units, CFO, Equity Compensation